Pluri Inc

PLUR

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

ASX healthcare giant remains well positioned despite share slump

We welcome the CEO change at CSL but relatively soft plasma performance will postpone recovery
stocks

Australian bank remains overvalued despite strong result

When strong fundamentals meet persistent valuation headwinds.
stocks

Chart of the Week: Soft earnings growth outlook for Australian banks

The latest take from our equity research analysts.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,281.8041.30-0.44%
CAC 408,418.19104.951.26%
DAX 4025,123.43267.281.08%
Dow JONES (US)50,121.4066.74-0.13%
FTSE 10010,514.3042.190.40%
HKSE27,032.54233.84-0.86%
NASDAQ23,066.4736.01-0.16%
Nikkei 22557,639.8410.70-0.02%
NZX 50 Index13,531.4824.200.18%
S&P 5006,941.470.34-0.00%
S&P/ASX 2009,043.5018.50-0.20%
SSE Composite Index4,134.022.030.05%

Market Movers